Abstract
While sentinel lymph node (SLN) sampling has been established for low-risk endometrial cancer, few data exists on high-risk histologies. This study aims to measure the accuracy of immediate intraoperative SLN biopsy with frozen section in high-risk endometrial cancer. Patients diagnosed with endometrial cancer of high-grade histology (grade 3 endometrioid, clear cell, serous, carcinosarcoma, de- or undifferentiated histology) between 2014 and 2019 at a single institution who underwent SLN mapping, followed by pelvic lymphadenectomy with or without para-aortic lymphadenectomy were included. SLNs were assessed intraoperatively using multiple frozen sections and H&E staining. Lymph node metastases detected by SLN biopsy were compared with complete lymphadenectomy specimens.
35 patients with high-grade endometrial cancer histology underwent SLN mapping followed by lymphadenectomy. In 34 of 35 (97%) of these patients mapping with at least one SLN was successful. Positive SLNs were identified in 7/34 patients (20.6%). There were no patients who had positive lymph nodes on complete lymphadenectomy without a positive SLN, resulting in 100% sensitivity, and 0% false-negative rate.
SLN mapping using intraoperative frozen sections in high-risk endometrial cancer demonstrated 100% sensitivity and 0% false-negative rate, provides immediate feedback on successful SLN mapping and valuable intraoperative information on the disease status guiding the intraoperative decision for completion lymphadenectomy.
Highlights
Intraoperative SLN assessment in high-grade endometrial cancer by frozen section.
100% sensitivity and 0% false-negative rate compared to complete lymphadenectomy.
Protocol provides immediate intraoperative feedback on successful SLN mapping.
Protocol helps inform surgeon’s decision to proceed with complete lymphadenectomy.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was received.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Stanford IRB Protocol Number: IRB-41259
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
IRB Protocol Number: IRB-41259
Disclosure: The authors have nothing to disclose.
Declarations
Funding: there are no sources of funding to disclose
Conflicts of interest/Competing interests: Sarah Miller, MD, Mahkam Tavallaee, MD, Malte Renz, MD, PhD, Ann K Folkins, MD and Amer Karam, MD declare that they have no conflict of interest
Ethics approval: Protocol Number IRB-41259
Consent to participate: not applicable Consent for publication: not applicable
Availability of data and material: The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary material.
Code availability: not applicable
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary material.
